Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of H5N1 Vaccine in Primed vs Unprimed Adults
NCT00478816Phase 2Completed
- Sponsor
- Novartis
- Start
- May 2007
- Primary completion
- Feb 2009
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of Audenz in Avian influenza H5N1 (H5N1) (2 arms), sponsored by Novartis. Primary endpoints: Cell-mediated immunity at Day 202 and Antibody response (HI, MN, SRH) at Day 202. Started May 2007; status: completed.
02
Drugs
Audenz
03
Conditions
Avian influenza H5N1 (H5N1)
Beyond the preview
Go deeper on NCT00478816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00478816.